Production & Sales

Abzena signs manufacturing and bioconjugation deal with Telix

UK-based life sciences group Abzena has signed GMP manufacturing and bioconjugation agreements with Australia-based Telix Pharmaceuticals.

Starpharma licenses VivaGel BV to Mundipharma for Europe

Starpharma and Mundipharma have signed a licence agreement for the sales and marketing rights to VivaGel BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America.

Takeda to sell Techpool to Chinese JV partners

Takeda Pharmaceutical has agreed to divest its its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma (Techpool), a China-based firm focused on urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care, to its joint venture (JV) partners for $280m.

Biopharmaceutical firm Accent Therapeutics launches with $40m financing

Accent Therapeutics has been launched with $40m Series A financing for precision cancer treatments targeting RNA-modifying proteins.

Amryt, Aegerion sign expanded deal for Lojuxta capsules

Amryt has signed an agreement with Aegerion Pharmaceuticals to expand its exclusive licence agreement for Lojuxta (lomitapide) into Russia and the Commonwealth of Independent States (CIS), as well as the non-EU Balkan states.

Takeda agrees to acquire Shire for £45.3bn

Takeda Pharmaceutical has agreed to acquire Ireland-based rare disease biotech company Shire in a cash-cum stock deal worth around £45.3bn.

Alkermes launches award program for research on CNS disorders

Alkermes has launched a new competitive awards program called the ALKERMES Pathways Research Awards Program to support the next generation of researchers working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders.

Endo to buy Somerset Therapeutics for $190m

Endo International has agreed to acquire New Jersey-based Somerset Therapeutics, that develops and markets sterile injectable and ophthalmic drugs, and the business of its India-based affiliate Wintac, which operates as Somerset's contract developer and manufacturer.

Shire considers Takeda’s revised £46bn takeover offer

Shire’s board said that it is willing to recommend Takeda Pharmaceutical’s revised acquisition offer of £46bn to its shareholders.